J&J snags rights to a gene therapy portfolio from little MeiraGTx, a spinoff from Sam Waksal’s Kadmon
After getting a quick lesson on little MeiraGTx’s gene therapy efforts — including their home made on/off switch — J&J is going all in. And like other deals it’s made recently, J&J’s research organization under Mathai Mammen is demonstrating its enthusiasm for small biotechs that are short on history and long on promise.
The pharma giant followed up on the initial research alliance they signed last fall with the biotech and snapped up commercial rights to a slate of clinical-stage, once-and-done development programs aimed at eye diseases. J&J will pay $100 million in a cash upfront for the deal and is putting another $340 million on the table in milestones.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.